SCHEMBL6760798

SCHEMBL6760798

[CH2]Cc1ccc(C(C)(C)C)cc1O[SiH](C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
HTR1D P28221 4/20 0.33
KDM4E B2RXH2 2/20 0.33
ATM Q13315 1/20 0.33
CYP2D6 P10635 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MAPT P10636 2/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
RXRA P19793 1/20 0.31
RXRB P28702 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8119764 0.83 CYP2C19 (0.38) CYP2C19CYP1A2CA1CA2CA9
SCHEMBL8113705 0.83 KLF10 (0.39) CYP2C19CYP1A2CA1CA2CA9
SCHEMBL4521923 0.78 CYP1A2 (0.34) CYP2C19CYP1A2CA1CA2CA9
SCHEMBL7586102 0.78 CYP2C19 (0.34) CYP2C19CYP1A2CA1CA2CA9
SCHEMBL6667896 0.77 CA1 (0.39) CYP2C19CYP1A2CA1CA2CA9
SCHEMBL7999289 0.76 NPSR1 (0.40) CYP2C19CYP1A2CA1CA2CA9
SCHEMBL4266306 0.76 NPSR1 (0.51) CYP2C19NPSR1RXRARXRBRXRG
SCHEMBL4261597 0.75 TP53 (0.41) CYP2C19CA1CA2CA9HTR1D
SCHEMBL7535667 0.74 NPSR1 (0.38) CYP2C19ALDH1A1ALOX15HSD17B10TDP1
SCHEMBL7355054 0.74 CA1 (0.39) CYP2C19CYP1A2CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6723860-B2 7a-alkoxy-4H-pyrano[3,2-d]-oxazol-2(3H)-one and process for producing the same UBE INDUSTRIES, LTD. (JP) 2004-04-20 US disclosed
EP-1207162-B1 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same UBE INDUSTRIES (JP) 2004-02-25 EP disclosed
US-20020072612-A1 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same UBE INDUSTRIES, LTD. (JP) 2002-06-13 US disclosed
EP-1207162-A1 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same Ube Industries, Ltd. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072612-A1 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same ACSL1, ACSL4, ACSL3 CYP2C19 455/4885CYP1A2 110/4885CA1 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.